Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Digestive Diseases and Sciences

Volumn 60, Issue 12, 2015, Pages 3801-3813

  Fabrizi, Fabrizio ^a,b   Verdesca, Simona ^a   Messa, Piergiorgio ^a   Martin, Paul ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b University School of Medicine   (United States)

Author keywords

Adult population; Chronic kidney disease; Hepatitis C; Meta analysis; Proteinuria

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LONGITUDINAL STUDY; META ANALYSIS; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; QUALITY CONTROL; RISK FACTOR; SEROLOGY; STRATIFICATION; SYSTEMATIC REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION; HEPATITIS C;

HEPATITIS C; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84946499608     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3801-y     Document Type: Article

References (52)

1. Eggers P. Has the incidence of end-stage renal disease in the USA and other countries stabilized ? Curr Opin Nephrol Hypertens. 2011;20:241–245.
2. Pol S, Vallet-Pichard A, Corouge M, Mallet V. Hepatitis C: epidemiology, natural history, and therapy. Contr Nephrol. 2012;76:1–9.
3. Perico N, Cattaneo D, Bibkov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207–220.
4. El-Serag H, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439–1445.
5. Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulo-interstitial injury. Am J Kidney Dis. 2003;41:767–775.
6. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol. 2005;140:498–506.
7. Gupta S, Eustace J, Winston J, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
8. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008;73:S1–S99.
9. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–e34.
10. Poynard T, Conn H. The retrieval of randomised clinical trials in liver diseases from medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials. 1985;6:271–279.
11. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute website. Available: http:/www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 16 Aug 2012.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
14. Petitti D. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20:3625–3633.
15. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistencies in meta-analysis. Br Med J. 2003;327:557–560.
16. Chen Y, Chiou W, Su Y, Hwang S. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrol. 2013;14:187.
17. Lin M, Chiu Y, Lee C, et al. Factors associated with CKD in the elderly and nonelderly population. Clin J Am Soc Nephrol. 2013;8:33–40.
18. Tsui J, Vittinghoff E, Shlipak M, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–1276.
19. Moe S, Pampalone A, Ofner S, Rosenman M, Teal E, Hiu S. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885–892.
20. Asrani S, Buchanan P, Pinski B, Rey L, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8:79–84.
21. Hofmann J, Torner A, Chow W, Ye W, Purdue M, Duberg A. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev. 2011;20:326–330.
22. Butt A, Wang X, Fried L. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396–402.
23. Su F, Su C, Chang S, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553–560.
24. Chen Y, Lin H, Li C, Lee M, Su Y. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85:1200–1207.
25. Lee J, Lin M, Chang J, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLOS One. 2014;9:e100790.
26. Molnar M, Alhourani H, Wall B, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495–1502.
27. Tsui J, Vittinghoff E, Shlipak M, O’Hare A. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174.
28. Dalrymple L, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715–721.
29. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res. 2008;38:775–783.
30. Lee J, Lin M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan. A cross-sectional study. Am J Kidney Dis. 2010;56:23–31.
31. Li W, Lee Y, Chen I, Wang S, Hsiao C, Loke S. Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease. J Viral Hepat. 2014;21:706–715.
32. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–290.
33. Huang J, Chuang W, Dai C, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link ? J Intern Med. 2006;260:255–262.
34. Yanik E, Lucas G, Vlahov D, Kirk G, Mehta S. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol. 2010;5:1836–1843.
35. Rhee M, Schmid C, Stevens L, Forrester J. Risk factors for proteinuria in HIV-infected and—uninfected Hispanic drug users. Am J Kidney Dis. 2008;52:683–690.
36. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:549–557.
37. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015. doi:10.1111/jvh.12411.
38. Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS. 2008;22:1799–1807.
39. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effects of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol. 2000;11:690–699.
40. Crook E, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187–2191.
41. Noureddine L, Usman S, Yu Z, Moorthi R, Moe S. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32:311–316.
42. Arase Y, Suzuki F, Kawamura Y, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res. 2011;41:946–954.
43. Bergman S, Accort N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684–689.
44. Hsu Y, Lin J, Ho H, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293–1302.
45. Ble M, Aguilera V, Rubin A, et al. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl. 2014;20:25–34.
46. Garg S, Hoenig M, Edwards E, et al. Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection. AIDS Patient Care. 2011;25:135–141.
47. Mangia A, Ripoli M. Insulin resistance, steatosis, and hepatitis C virus. Hepatol Int. 2013;7:S782–S789.
48. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signalling 3. Am J Pathol. 2004;165:1499–1508.
49. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes. Direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848.
50. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality ? J Viral Hepat. 2012;1:601–609.
51. Petta S, Macaluso F, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more ? Gut. 2014;63:369–375.
52. Boddi M, Abbate R, Chellini B, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47:72–75.